Patents by Inventor Carolyn Enever
Carolyn Enever has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140187750Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: Glaxo Group LimitedInventors: Carolyn ENEVER, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson
-
Patent number: 8685895Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: GrantFiled: December 4, 2009Date of Patent: April 1, 2014Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian M Tomlinson
-
Publication number: 20130230519Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14-10, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: August 12, 2011Publication date: September 5, 2013Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Malgorzata Pupecka-Swider, Oliver Schon
-
Publication number: 20130202597Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: August 12, 2011Publication date: August 8, 2013Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Haren Arulanantham, Thil Dinuk Batuwangala, Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
-
Publication number: 20130129746Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: May 20, 2011Publication date: May 23, 2013Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon, Malgorzata Pupecka-Swider
-
Patent number: 8398979Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: June 4, 2008Date of Patent: March 19, 2013Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20130022605Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.Type: ApplicationFiled: July 13, 2011Publication date: January 24, 2013Inventors: Neil D. Brewis, Benjamin P. Woolven, Steven Holmes, Ian M. Tomlinson, Jennifer Lee, Carolyn Enever, Amrik Basran, Kate Jones, Ruud de Wildt, Stanislas Blein
-
Patent number: 8357780Abstract: The invention relates to anti-IL-1R1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: June 3, 2008Date of Patent: January 22, 2013Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20120253017Abstract: The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention describes a construct wherein the tissue specific marker is a muscle specific marker molecule. Such a construct may be used in a pharmaceutical composition for use in muscle regeneration or heart disease.Type: ApplicationFiled: May 26, 2010Publication date: October 4, 2012Inventors: Victoria Ballard, Thil Dinuk Batuwangala, Edward Coulstock, Elena De Angelis, Jay Edelberg, Carolyn Enever, Steve Holmes, Zahra Ja wad-Alami
-
Publication number: 20110305696Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: February 17, 2010Publication date: December 15, 2011Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Christopher Plummer, Oliver Schon
-
Publication number: 20110301335Abstract: The invention relates to anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: ApplicationFiled: February 17, 2010Publication date: December 8, 2011Inventors: Stephen Duffield, Carolyn Enever, Haiqun Liu, Oliver Schon, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20110300158Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: February 17, 2010Publication date: December 8, 2011Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
-
Publication number: 20110229458Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: December 4, 2009Publication date: September 22, 2011Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian M. Tomlinson
-
Publication number: 20110086019Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 3, 2008Publication date: April 14, 2011Applicant: Domantis LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Armin Sepp
-
Publication number: 20100291103Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: ApplicationFiled: June 3, 2008Publication date: November 18, 2010Applicant: Domantis LimitedInventors: Micheal Steward, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever, Laurent Jespers, Thil Dinuk Batuwangala
-
Publication number: 20100266616Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 4, 2008Publication date: October 21, 2010Applicant: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20100260763Abstract: The invention relates to anti-IL-1R1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 3, 2008Publication date: October 14, 2010Applicant: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20100254995Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: ApplicationFiled: June 3, 2008Publication date: October 7, 2010Applicant: Domantis LimitedInventors: Michael Steward, Malgorzata Pupecka, Ian Thomlinson, Carolyn Enever, Laurent Jespers, Thil Dinuk Batuwangala
-
Publication number: 20100254972Abstract: The invention relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the GI tract or pulmonary tissue of a human. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, combining the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, eg for treating disease or conditions of GI tract or pulmonary tissue in humans.Type: ApplicationFiled: June 3, 2008Publication date: October 7, 2010Applicant: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20100247515Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: ApplicationFiled: June 4, 2008Publication date: September 30, 2010Applicant: Domantis LimitedInventors: Michael Steward, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever, Laurent S. Jespers, Thil Dinuk Batuwangala